Abstract | BACKGROUND: METHODS: RESULTS: A total of 240 subjects were enrolled, and 239 received the intervention. External cephalic version was successful in 123 (51.5%) of 239 patients. Compared with bupivacaine 2.5 mg, the odds (99% CI) for a successful version were 1.0 (0.4 to 2.6), 1.0 (0.4 to 2.7), and 0.9 (0.4 to 2.4) for bupivacaine 5.0, 7.5, and 10.0 mg, respectively (P = 0.99). There were no differences in the cesarean delivery rate (P = 0.76) or indication for cesarean delivery (P = 0.82). Time to discharge was increased 60 min (16 to 116 min) with bupivacaine 7.5 mg or higher as compared with 2.5 mg (P = 0.004). CONCLUSIONS: A dose of intrathecal bupivacaine greater than 2.5 mg does not lead to an additional increase in external cephalic procedural success or a reduction in cesarean delivery.
|
Authors | Laurie A Chalifoux, Jeanette R Bauchat, Nicole Higgins, Paloma Toledo, Feyce M Peralta, Jason Farrer, Susan E Gerber, Robert J McCarthy, John T Sullivan |
Journal | Anesthesiology
(Anesthesiology)
Vol. 127
Issue 4
Pg. 625-632
(10 2017)
ISSN: 1528-1175 [Electronic] United States |
PMID | 28723831
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anesthetics, Local
- Bupivacaine
|
Topics |
- Adult
- Anesthetics, Local
(administration & dosage)
- Breech Presentation
(prevention & control)
- Bupivacaine
(administration & dosage)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Injections, Spinal
- Pregnancy
- Prospective Studies
- Version, Fetal
(statistics & numerical data)
|